ArticleFrontiers in immunology2026
Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Increasing evidence suggests that autoimmune responses are involved in the pathogenesis of age-related macular degeneration (AMD). This study aimed to characterize changes in serum autoantibody-captured retinal antigens in patients with different AMD subtypes, in order to gain further insight into the immunological mechanisms associated with AMD progression. Methods: Serum samples were collected from healthy controls (CTRL, n = 15) and patients with early AMD (n = 15), intermediate AMD (Int. AMD, n = 15), late AMD (n = 15), neovascular AMD with type 1 macular neovascularization (nAMD type 1, n = 10), and neovascular AMD with type 2 macular neovascularization (nAMD type 2, n = 10). Serum antibodies were isolated using Protein G magnetic beads and incubated with porcine retinal lysates to capture antigen-antibody complexes. After elution, the captured retinal antigens were subjected to proteomic analysis. Results: Mass spectrometry identified 91 differentially captured retinal antigen targets across AMD subtypes. Compared with controls, 11, 9, 11, 18, and 22 retinal antigen targets were significantly increased in serum samples from patients with early AMD, intermediate AMD, late AMD, nAMD type 1, and nAMD type 2, respectively. Conversely, 14, 11, 9, 10, and 20 retinal antigen targets were decreased in the corresponding AMD subtypes, respectively (FDR < 0.05; p < 0.05). Selected mass spectrometryderived retinal antigen targets were further evaluated in serum and tear samples using antigen microarray analysis. Consistent with the proteomics results, anti-ATP5A1, anti-HIST2H2AA3, and anti-PFKM autoantibody levels were significantly increased in tears from patients with nAMD type 2 (p = 0.03, p = 0.01, and p = 0.04, respectively). In addition, anti-FTH1 autoantibody levels were decreased in serum from patients with nAMD type 1. Discussion: Comprehensive screening of serum autoantibody-captured retinal antigens across AMD stages, together with pathway enrichment and STRING network analyses, revealed subtype-specific immune alterations. These findings provide new insights into the immunopathological features of AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.